• Publications
  • Influence
Allergen immunotherapy: a practice parameter third update.
These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American Col- lege of Allergy, Asthma &Expand
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.
Subgroup analyses suggest the risk may be greater in African Americans compared with Caucasian subjects and whether this risk is due to factors including but not limited to a physiologic treatment effect, genetic factors, or patient behaviors leading to poor outcomes remains unknown. Expand
Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report.
An expert team was nominated to develop a comprehensive consensus report on the mechanisms of AIT and its use in clinical practice, as well as unmet needs and ongoing developments in AIT. Expand
Sublingual immunotherapy: World Allergy Organization position paper 2013 update
“Raising public awareness about sublingual immunotherapy”, as a need for patients, and strategies to increase awareness of allergen immunotherapy (AIT) among patients, the medical community, all healthcare stakeholders, and public opinion are reported in detail. Expand
Sublingual immunotherapy: a comprehensive review.
Despite clear evidence that SLIT is an effective treatment, many questions remained unanswered, including effective dose, treatment schedules, and overall duration of treatment, and an assessment of the cost/benefit ratio of the treatment cannot be made. Expand
Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract.
Injections of peanut extract increase the tolerance of patients with peanut allergy to oral ingestion of peanuts, even during maintenance injections, which result in repeated systemic reactions in most patients. Expand
Onset and persistence of childhood asthma: predictors from infancy.
3 proved to have significant univariate relationships with asthma between ages 6 and 8: elevated IgE levels measured when the children were 6 months of age, global ratings of parenting difficulties measured when infants were 3 weeks old, and higher numbers of respiratory infections in the first year of life. Expand
An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
There is an urgent need for rigorous, long-term, double-blind, placebo-controlled randomized clinical trials with an efficacy criterion that reflects the particular features of HDM-induced allergic disease. Expand
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast.
Symptomatic patients on low-dose ICS therapy had significantly greater improvement in asthma control when switched to the FP/Salm Combo than when montelukast was added to ICS Therapy. Expand
Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.
A single dose of IL-4R appears safe and effective in moderate asthma, and the 1,500 microg dose appears as safe but significantly more effective than the 500microg dose. Expand